0. Advocacy Webpage Graphics-Narrow-Cover It

One of the greatest barriers to the successful treatment of individuals with addiction is the current healthcare financing system for much of addiction treatment, which offers little support for the coordination of behavioral, social, and psychological services that patients often need in addition to medication. This segregation and lack of coordination has made it difficult for many individuals to receive comprehensive care and access the most effective and appropriate treatments.

According to the Substance Abuse and Mental Health Services Administration, fewer than one in ten Americans with a substance use disorder received treatment. We must overhaul our addiction treatment infrastructure so that it facilitates the successful treatment of individuals with substance use disorder through coordinated, rather than siloed delivery of care.


Learn how ASAM is leading the national movement to increase access to and improve the quality of evidence-based addiction treatment.

Featured Public Policy Statements

1. bup c

Patient Review and Restriction (PRR) Programs

Learn ASAM's position on Patient Review and Restriction (PRR) or pharmacy "lock-in" programs.

medical-specialist-FI b

Inclusion of Addiction Specialist Physicians in Managed Behavioral Health Care Organization In-Network Provider Panels

Managed behavioral health care organizations should accept non-psychiatrist physicians who are addiction treatment specialists on their provider panels.

"The current physician reimbursement structure does not account for all the services that patients with an opioid use disorder need to progress to successful treatment and recovery."

-Dr. Shawn Ryan, MD, MBA, ABEM, ABAM, FASAM
Chair of ASAM's Payer Relations Committee



Section 1115 Waivers

Learn how states are using Section 1115 Waivers to waive federal requirements that cannot be waived by a State Plan Amendment.
Billing & Coding

Billing & Coding

Access information on the language of reimbursement for addiction treatment services.


See what ASAM is doing to increase insurance coverage for addiction treatment.

Related News

  • March 14, 2019

    ASAM Writes to FDA Regarding Need for More Medication Treatment Options for Patients with SUD

    The dearth of FDA-approved pharmacotherapies for the treatment of substance use disorder (SUD) prompted ASAM to write to the Food and Drug Administration urging them to take into consideration the need for access to multiple treatment options for clinicians and their patients as they consider applications for new products to treat SUD.
  • January 10, 2019

    New Taxonomy Code

    Given the recognition of addiction medicine as a medical subspecialty by ABMS, with an established curriculum and training standards and a new certification pathway, ASAM believed it was timely and appropriate to request a new taxonomy code that would capture the distinctive nature of this area of specialty practice.
  • December 19, 2018

    ASAM Submits Comments to FDA Regarding Strategies to Increase Naloxone Availability

    ASAM submitted comments to the Food and Drug Administration (FDA) in response to a request for comment ahead of a public advisory committee meeting regarding strategies to increase the availability of naloxone products intended for use in the community.